P.02Phase 2/3 study of Arimoclomol in sporadic inclusion body myositis: study design

Sporadic inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy occurring in patients over the age of 45 years. IBM muscle displays both inflammatory and degenerative features, yet immune suppression has proven to be ineffective. Modulating the cytoprotective "heat shock response" (HSR) represents a therapeutic strategy targeting both inflammation and degeneration. Arimoclomol is an orally administered pharmacological agent that can up-regulate the HSR by amplifying heat shock protein expression.

Source: Neuromuscular Disorders - September 30, 2019 Category: Neurology Authors: P. Machado, R. Barohn, M. McDermott, T. Blaetter, T. Lloyd, A. Shaibani, M. Freimer, A. Amato, E. Ciafaloni, T. Burns, T. Mozaffar, S. Gibson, M. Wicklund, D. Saperstein, T. Levine, C. Sundgreen, A. Aaes-J ørgensen, T. Liu, L. Herbelin, M. Hanna, M. Dima Source Type: research